44P A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
Titel:
44P A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
Auteur:
Yun, T. Shin, S.J. Kim, D-W. Yun, C.H. Heo, S. Hyun, B. Kim, Y.S. Kim, J.S. Moon, Y.W.